Diamond Headache Clinic   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Chicago IL United States (1972)

Organization Overview

First Clinical Trial
2005
NCT00293657
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Diamond Headache Clinic | Merle Diamond

Active Ingredients

Drugs in Phase 4 Trials (3)

erenumab (aimovig) (1 trial)

galcanezumab-gnlm (emgality) (1 trial)

sumatriptan (zecuity) (1 trial)

Drugs in Phase 3 Trials (3)

acetaminophen (tylenol) (1 trial)

caffeine (1 trial)

rizatriptan (maxalt) (2 trials)

Drugs in Phase 2 Trials (1)

lornoxicam (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cluster Headache (Phase 4)

Headache (Phase 4)

Migraine Disorders (Phase 4)

Migraine with Aura (Phase 3)

Migraine without Aura (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 7